In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme

Michael Huband, Paul R. Rhomberg, Christopher Blankers, Michael A. Pfaller, Mariana Castanheira

JMI Laboratories, North Liberty, Iowa, USA

In vitro activity of omadacycline against infrequently encountered pathogens

Objective


Determine the *in vitro* activity of omadacycline and comparators against infrequently encountered Gram-positive, Gram-negative, and anaerobic bacterial pathogens from the SENTRY Surveillance Programme.

Conclusions

- Omadacycline demonstrated potent *in vitro* activity against infrequently encountered Grampositive, Grampositive, and anaerobic bacterial clinical isolates, including strains demonstrating resistance to other drug classes.
- Many bacteria had MIC₉₀ deemed susceptible to omadacycline when applying established breakpoints for a similar genus or organism group.

Acknowledgements

This study was funded by Paratek Pharmaceuticals, Inc.



To obtain a PDF of this poster: Scan the QR Code or visit <u>here</u>.